PRR12: A Protein Involved in Cell Cycle Regulation and Drug Target

Target Name: PRR12

NCBI ID: G57479

PRR12

PRR12: A Protein Involved in Cell Cycle Regulation and Drug Target

PRR12 (KIAA1205) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the cell cycle, and is involved in the development and maintenance of normal cell structure and function. Mutations in the PRR12 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a drug target (or biomarker), PRR12 is of great interest to researchers because of its potential to interfere with the development and progression of these diseases.

One of the defining features of PRR12 is its role in the regulation of the cell cycle. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. PRR12 is involved in the regulation of the G1 phase of the cell cycle, which is the stage at which the cell prepares for cell division. During this phase, PRR12 helps to ensure that the cell has enough chromosomes to divide normally.

PRR12 is also involved in the regulation of the G2 phase of the cell cycle, which is the stage at which the cell prepares for cell division. During this phase, PRR12 helps to ensure that the cell has enough chromatin to be replicated. Replication of chromatin is necessary for the development and maintenance of normal cell structure and function.

In addition to its role in the cell cycle, PRR12 is also involved in the regulation of cell growth and differentiation. During the G1 phase of the cell cycle, PRR12 helps to ensure that the cell grows and performs its normal functions. In addition, PRR12 is involved in the regulation of stem cell properties, and is thought to play a role in the development and maintenance of stem cells.

Mutations in the PRR12 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that mutations in the PRR12 gene are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, mutations in the PRR12 gene have also been linked to an increased risk of cancer, particularly breast cancer.

As a drug target (or biomarker), PRR12 is of great interest to researchers because of its potential to interfere with the development and progression of these diseases. Researchers are currently working to develop drugs that can specifically target PRR12 and prevent or reverse its effects on the cell cycle. This research has the potential to lead to new treatments for a variety of diseases.

In conclusion, PRR12 (KIAA1205) is a protein that is expressed in various tissues of the body, and is involved in the regulation of the cell cycle. Mutations in the PRR12 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a drug target (or biomarker), PRR12 is of great interest to researchers because of its potential to interfere with the development and progression of these diseases. Further research is needed to understand the full role of PRR12 in the regulation of the cell cycle and to develop new treatments for diseases associated with its mutations.

Protein Name: Proline Rich 12

The "PRR12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets